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Prognosisportant for tumor cell growth and survival. Telomere length (TL) is determined
by the balance between positive and negative factors impacting telomere homeostasis. In the last decade, TL
has emerged as a promising clinical marker for risk and prognosis prediction in patients with malignant
disorders. Tumor TL, as well as TL in healthy tissues such as peripheral blood, may carry valuable information
for future treatment strategies. Here we discuss the present status of TL as a biological marker in cancer
patients.
© 2009 Elsevier B.V. All rights reserved.1. IntroductionTelomere maintenance is a multifaceted process involving a large
set of interacting factors, gathering at the chromosome end where
the telomere is located. The main players in this process are the
telomerase RNA–protein complex and the shelterin proteins, but
also chromatin modifying factors are important. In the normal
somatic cell, telomere shortening occurs with each cell division. It is
well recognized that telomerase activity (TA), detectable in the
majority of tumor cells, is the main positive power for telomere
preservation and elongation. The TA level is to a large extent
determined by regulation of the hTERT (telomerase reverse
transcriptase) and hTR (telomerase RNA) genes. In addition, TA
regulation occurs in a cell type speciﬁc manner. Furthermore,
besides being activated in most malignant tumors, many normal cell
types express telomerase at speciﬁc differentiation steps, often at
the progenitor stage.
It is important to recognize that there is no obvious correlation
between TL and TA. The actual TL is the result of all forces affecting
telomere homeostasis, such as replication rate, regulatory proteins,
telomerase expression, epigenetics etc. Environmental factors are also
likely to have an impact onTL. As an example, oxidative stress has been
shown to increase the telomere attrition rate [1]. Analyses in tumors
have indicated that TA canbe of value as a diagnostic and/or prognostic
tool [2], but there is no consensus regarding its applicability in the
clinical setting.h Cancer Society, Lion's Cancer
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ll rights reserved.There is growing evidence that TL carries information that may be
of clinical importance for cancer patients. It is well established that TL
is important for senescence in normal cells. Malignant cells in general
have shorter telomeres than their normal counterparts and there
seems to be a connection between telomere shortening, genetic
aberrations and risk of transformation [3]. The interest of investigating
TL as a potential clinical biomarker in cancer has grown considerably
in recent years. The prognostic value of TL in solid tumors was
previously reviewed by Bisofﬁ et al. [4], and its importance in
hematological malignancies has also been extensively investigated
and previously reviewed [5,6].
The vast majority of studies in the ﬁeld have been performed on
tumor samples, but there are also investigations on blood cell TL and its
possible relation to cancer risk and prognosis. It is important to
discriminate between these approaches, since they focus on two
completely different tissue compartments with, most likely, different
telomere dynamics. When tumor DNA is studied, TL reﬂects the
cumulative result of a variety of tumor-associated factors with impact
on telomere homeostasis. TL in peripheral blood is often used as a proxy
for TL in other healthy tissues. The fact that TL in peripheral blood may
carry clinical information for cancer patients, as has been indicated by a
growing number of studies, is intriguing. One question to be solved,
however, is whether altered blood TL can contribute to disease
development, or whether the TL alterations arise as a consequence of
the disease. The latter casewould suggest that an altered blood TL is the
result of unknown mechanisms associated with the presence of a
malignant tumor in the body. There is also the possibility that TL
alterationsdetected in blood cellsmaycause andbe causedbydisease. In
anycase, previousdata indicate that bloodTLmayserve bothas amarker
for cancer risk and as an independent prognostic marker for survival.
Thus, both tumor TL and TL in peripheral blood may carry
informationwith important clinical implications. In the present review
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issue that is discussed is the technique used for TL measurement. It is
an issue for debate and for this reason we think it appropriate to start
with a description of the main methods available, including our view
on their pros and cons.
2. Methods to determine telomere length
Different methods are in use for telomere length determination, all
of which are based on hybridization to the telomeric repeat sequence.
The traditional method, Southern blotting, has become established as
the “golden standard” for TL determinations. In Southern blotting,
restriction enzyme cut DNA is separated by electrophoresis and
transferred to a membrane. Hybridization is performed with a labeled
telomere-speciﬁc probe and the end-result is a smear like signal,
reﬂecting the heterogeneous length character of the telomeres. The
method is, for example, useful to evaluate telomere variability
between and within different cell populations. Various algorithms
can be used to assign the TL “smear” an accurate length in kilo base
pairs, either as mean or peak values. However, until a common
approach is used for this calculation it is still hard to directly compare
TL values from different laboratories. A drawback with the technique
is also that rather much DNA is needed (5–10 μg). In addition, the
method is time consuming which limits its value when analyses of
large series of samples are needed.
An enormous amount of clinical samples are collected in biobanks
in pathology laboratories all over theworld.Many of these samples are
in the form of parafﬁn embedded tissues, including large sets of
tumors of interest for retrospective analyses. DNA extracted from
formalin ﬁxed and parafﬁn embedded material is of poor quality and
unsuitable for Southern blotting. A slot blot methodology has been
proposed as an alternative to estimate the total telomere DNA content
in such samples [7,8]. Brieﬂy, denatured DNA is cross-linked to a ﬁlter
and hybridized to a tag-labeled telomere-speciﬁc probe. A quantiﬁable
signal is detected by using an antibody directed to the tag. The slot blot
method is a promising option for analysis of parafﬁn embedded
tissues, providing at least rough estimates of the TL. The use of PCR
ampliﬁcation, as described by Cawthon in 2002 [9] (see further
below), could theoretically be an interesting alternative for TL
determination in samples extracted from parafﬁn sections. In our
laboratory, the PCR method have given an acceptable correlation to
Southern blot data when applied on DNA from bone marrow and
lymph node sections (Grabowski et al., unpublished data), but for
solid tumors this approach has been unsuccessful [[10]+ unpublished
data from our laboratory].
Quantitative ﬂuorescence in situ hybridization, Q-FISH, for quanti-
ﬁcation of telomere signals can be very informative in analyses of
metaphase spreads or interphase cells [11,12]. This technique can also
be used to estimate TL in parafﬁn sections. One advantage is that
microscopically identiﬁed cells can be selected for examination. By this
method, TL alterations in preneoplastic cells and early neoplasias have
been identiﬁed in various tissues [13,14]. It is, however, difﬁcult to
achieve a reliable (semi)quantiﬁcation of the TL, due to factors affecting
e.g. the hybridization process (like tissue condition at time for ﬁxation,
ﬁxation time, ﬁxation efﬁciency, section thickness, etc.), making it hard
to compare results from different laboratories. The Q-FISH technique is
very useful in experimental settings but has so far not been used for
prognostication in tumor patients.
Flow cytometric analysis with a ﬂuorochrome-labeled telomere-
speciﬁc probe, ﬂow-FISH, is a laborious but very useful approach for TL
measurements in hematopoietic cells in suspension [15,16]. The
telomere content of individual cells can be obtained by this method,
and in combination with DNA staining, data on e.g. telomere
replication timing can be achieved [17]. Furthermore, immuno-
phenotyping and ﬂow-FISH can be performed simultaneously, giving
the possibility to analyze speciﬁc cell types within a mixture of cells.By including an internal control cell line in each assay, the
hybridization efﬁciency can be monitored and the control cells can
be used as a standard for TL quantiﬁcation [16].
A PCR based method for TL determination, Tel-PCR, was considered
“impossible” until Cawthon [9] described his approach, taking
advantage of a new primer design which minimized the risk for
primer dimer appearance. The data obtained by this method correlate
well with Southern blot results [9,18] and since it is PCR based, large
sets of samples can be analyzed within a limited time span. In
addition, the technique utilizes a small amount of DNA. Many
laboratories are now using the method, but it is not uniformly
accepted and the results are presented differently from laboratory to
laboratory. Although the method has been applied by many
researchers there is still a discussion to what extent the technique is
reproducible. We believe that this, at least partly, is due to technical
issues and a strict and detailed description of the method seems to be
needed. We have used the Tel-PCR technique since 2005 and ﬁnd it
satisfactory. The inter-assay coefﬁcient of variation for the method
ranges between 4 and 8% in our laboratory, which is in the range of
other reports [9,19,20]. In a very recent paper by Cawthon [21], a
multiplex version of the Tel-PCR assay was presented, showing high
reproducibility and very good correlation with Southern blot data.
This multiplex method may well be an attractive alternative for
telomere length measurements, allowing increased throughput and
reduced costs.
By taking advantage of chromosome speciﬁc subtelomeric
sequences Baird et al. [22] developed a PCR based technique for
detection of individual telomeres, the STELA (single telomere length
analysis) method. By this approach very short telomeres, not detected
by other methods, can be visualized [22]. The method is, however, at
its present stage laborious and not useful for large sets of samples or in
the diagnostic setting.
In conclusion, there are several useful approaches to determine the
TL and the choice depends largely on the questions asked. If single
telomeres are to be analyzed the Q-FISH or STELA methods can give
detailed information. TL of single cells in smears or sections can be
revealed by Q-FISH, whereas ﬂow-FISH is the method for cells in
suspension. For DNA extracted from fresh cell pellets or tissue samples
the options are Southern blotting and Tel-PCR and for DNA from
parafﬁn embedded material the slot blot technique seems most
promising. Warranted for the future, however, are standardized
protocols (e.g. for the Tel-PCR method), so that TL values or relative
TL values from different laboratories can be directly compared.
3. Telomere length as a prognostic indicator in hematological
malignancies
Independent of the technique used for TL measurements there are
convincing data suggesting that short telomeres in malignant
hematopoietic cell populations indicate progressive disease and
poor survival. A summary of published data in this ﬁeld is given in
Table 1 [18,23–40]. Especially for three disorders, myelodysplastic
syndrome (MDS), chronic myeloid leukemia (CML) and chronic
lymphocytic leukemia (CLL), the collected data from different
research groups seem to be in good agreement. A summary of these
ﬁndings are given below.
Within MDS a number of cytogenetically different subgroups are
included with a varied tendency for clinical progression and
development of acute leukemia. Early studies using Southern blotting
indicated that short TL was associated with the frequency of genomic
aberrations and to a more rapid clinical course [23,24]. The shortened
telomeres in MDS have been explained as a result of increased
proliferation of themalignant clone. A previous study [26], using ﬂow-
FISH, showed that CD34+ cells from MDS patients had shorter TL
compared to controls and, interestingly, that the TL in CD34+ cells
correlated with degree of apoptosis.
Table 1
Summary of studies investigating blood telomere length as a marker for risk and/or prognosis in hematopoietic malignancies
Tumor type Method for TL determination Main ﬁndings Reference
Myelodysplasia (MDS) Southern blot Indications that TL reduction was linked to disease evolution and poor
prognosis.
Ohyashiki et al. [23]
Southern blot Shortened TL associated with high frequency of cytogenetic
abnormalities, high incidence of leukemic transformation and a very
poor prognosis.
Ohyashiki et al. [24]
Southern blot TL shortening coupled to MDS subgroups and clinical progression. Sieglova et al. [25]
Flow-FISH MDS granulocytes and CD34+ cells had shorter telomeres than controls.
CD34+ TL correlated with CD34+ apoptosis.
Rigolin et al. [26]
Acute Myeloid Leukemia (AML) Flow-FISH TL shorter than in control granulocytes. Shortest telomeres found in
patients with multiple genetic aberrations.
Hartmann et al. [27]
Q-FISH AML with multiple genetic aberrations characterized by critically short
TL
Swiggers et al. [28]
Southern blot TL in acute promyelocytic leukemia positively correlated to
PML-RARα expression. Shortened TL coupled to poorer survival.
Ghaffari et al. [29]
Chronic Myeloid Leukemia (CML) Southern blot Shortened TL in 56% of the patients. Patients with normal TL seemed to
respond favorably to α-interferon therapy
Iwama et al. [30]
Southern blot Reduction in TL was associated with progression of disease Boultwood et al. [31]
Southern blot Telomere reduction correlated with time to accelerated phase Boultwood et al. [32]
Flow-FISH Data suggest that TL shortening can act as a marker for disease
progression in CML
Brümmendorf et al. [33]
Flow-FISH TL reduction most pronounced in high-risk score patients at diagnosis. Drummond et al. [34]
Chronic Lympho-cytic
Leukemia (CLL)
Southern blot TL inversely correlated to telomerase activity. Short TL and high
telomerase activity associated with shorter survival.
Bechter et al. [35]
Southern blot Short TL associated with unmutated immunoglobulin (IGHV) genes and
poor survival.
Hultdin et al. [36]
Tel-PCR By combining IGHV gene mutation status and TL new prognostic
subgroups were indicated.
Grabowski et al. [18]
Southern blot Suggest that TL can be used for reﬁned prognostication, especially for
patients with unmutated IGHV genes.
Ricca et al. [37]
Tel-PCR Short TL associated with high risk genetic aberrations, unmutated IgHV
genes, ZAP70 and CD38 expression. TL was an independent prognostic
indicator for treatment free survival.
Roos et al. [38]
Myeloma Southern blot High telomerase activity and short TL deﬁned a subgroup with poor
prognosis. Cytogenetic aberrations correlated with telomerase activity
and short TL.
Wu et al. [39]
Southern blot Shorter TL was associated with abnormal karyotype. Cottliar et al. [40]
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demonstrated that AML cells have shorter telomeres compared to
controls and that the shortest telomeres are found in cases with
multiple genetic aberrations. For acute promyelocytic leukemia, TL
was found to be positively associated with the PML-RARα fusion gene
expression and short telomeres with a poor response to arsenic
treatment [29].
In CML shortened telomeres is a common ﬁnding and in an early
study by Iwama et al. [30], the data indicated that a small subset of
CML cases with normal TL might respond favorably to interferon
treatment. Later investigations fromdifferent laboratories have shown
that short telomeres and increased telomere attrition rate in CML are
indicative of a progressive disease [31–34].
The ﬁrst study on TL in CLL indicated that TL could be a future
prognostic marker, showing that short telomeres and high telomerase
activity was associated with a shorter survival [35]. CLL can develop
from different types of B cells depending on their “relation” to the
germinal center. Hypermutation of immunoglobulin heavy chain
(IGHV) genes occur in normal germinal centers (GC) as an antigen
driven B cell response, and CLL can emerge from “pre-GC B cells”, i.e.
with unmutated IGHV genes, or from “GC B cells” (with mutated IGHV
genes). Also, telomerase is activated in GC leading to telomere
lengthening and therefore it was not surprising that TL in CLL was
associated with IGHV gene status [18,36–38]. These studies also
veriﬁed TL as a signiﬁcant prognostic marker in CLL, demonstrating
that short telomeres were associated with well recognized indicators
of poor prognosis such as unmutated IGHV genes, high expression of
CD38 and ZAP-70 and high risk genomic aberrations [18,36–38].
A similar pattern as forMDS andCLL has been indicated inmyeloma
for which two studies have reported that short telomeres correlatedwith cytogenetic aberrations [39,40]. A subgroup with poor prognosis
was deﬁned by high telomerase activity and short telomeres [39].
4. Telomere length as a prognostic indicator in solid tumors
A number of studies have reported that TL in solid tumors has
potential to be used as a prognostic indicator. The research area has
previously been reviewed [4] and an updated summary of published
data in the ﬁeld is given in Table 2 [41–59]. Several different tumor
types have been investigated regarding tumor TL and clinical
outcome. The majority of studies have found associations between
altered tumor TL, i.e. attrition and/or elongation, and a poor outcome.
The Grifﬁth group, using slot blot assays for assessing the total
telomere DNA content, has reported associations between reduced
telomere content and poorer survival in both breast and prostate
carcinomas [42–46]. Similarly, in sarcoma, short TL was linked to
genomic instability and poor survival [59]. In contrast, long
telomeres, or a high tumor to non-tumor TL ratio, have been coupled
to tumors of more advanced stages and a worse prognosis in
hepatocellular carcinoma [49], colorectal carcinoma [47,48], Barrett
carcinoma [53], and head and neck tumors [54]. In clear cell renal
cell carcinoma [55], we did not ﬁnd an association between tumor TL
and patient survival when comparing TL quartiles. However, there
was a trend to poorer survival in patients with a high tumor to non-
tumor TL ratio, and a positive correlation between TL ratio and tumor
size. In lung cancer, both telomere reduction and elongation has been
associated with a worse outcome [50–52]. Two studies have
investigated TL as a prognostic marker in neuroblastoma [56,57]. In
the most recent study [57], short TL predicted a favorable prognosis,
whereas in the ﬁrst study [56], short tumor TL was correlated with
Table 2
Summary of studies investigating telomere length as a prognostic indicator in solid tumors
Tumor type Method for TL determination Main ﬁndings Reference
Breast Southern blot Telomere shortening most pronounced in Grade 3 tumors. Shorter telomeres in
lymph node-negative tumors compared to lymph node-positive tumors.
Odagiri et al. [41]
Slot blot Reduced telomere DNA content associated with metastasis and aneuploidy. Grifﬁth et al. [42]
Slot blot Telomere DNA content correlated with stage and prognosis. Reduced telomere
content found to be an independent negative prognostic factor.
Fordyce et al. [43]
Slot blot Telomere DNA content predicted breast cancer-free survival interval and was
independent of 12 risk factors, including TNM stage and p53 status.
Heapy et al. [44]
Prostate Slot blot Reduced telomere DNA content associated with disease recurrence and poorer
survival.
Donaldson et al. [45]
Slot blot Reduced telomere DNA content predicted disease recurrence independent of
age at diagnosis, Gleason sum and pelvic node involvement.
Fordyce et al. [46]
Colorectal Southern blot TL positively correlated with tumor stage. High tumor to non-tumor TL ratio
(N0.90) associated with poorer overall survival.
Gertler et Al. [47]
Southern blot Long TL associated with a poor outcome. Favorable outcome for telomerase-
positive tumors with small tumor to non-tumor TL ratio (≤0.66) or TRF1
overexpression.
Garcia-Aranda et al. [48]
Hepatocellular Southern blot Advanced tumors with poor prognosis showed high telomerase activity, high
mitotic instability, long telomeres and a high tumor to non-tumor TL ratio
(N0.80).
Oh et al. [49]
Lung Southern blot Both telomere reduction and elongation observed but no signiﬁcant association
with prognosis shown.
Shirotani et al. [50]
Southern blot Alterations in tumor TL, i.e. reduction or elongation, associated with a worse
outcome.
Hirashima et al. [51]
Southern blot Short tumor TL was an independent negative prognostic factor. Frias et al. [52]
Oesophagus Southern blot Poor survival for patients with a high tumor to non-tumor TL ratio (N1.17).
TL ratio found to be an independent prognostic factor.
Gertler et al. [53]
Head and neck Southern blot Poor disease-free survival for patients with long tumor TL. Patel et al. [54]
Renal Tel-PCR No association between tumor TL and patient survival when comparing TL
quartiles. A trend to better survival found for patients with a low TL ratio
[≤ median (0.55)].
Svenson et al. [55]
Neuroblastoma Southern blot Short tumor TL correlated with advanced tumor stages, increased S-phase
fractions in tumor cells, and poor survival.
Hiyama et al. [56]
Southern blot Long or unchanged tumor TL associated with a poor outcome. Ohali et al. [57]
Glioblastoma multiforme Southern blot Tumors displaying an ALT phenotype with long telomeres had a better
prognosis compared to patients with non-ALT tumors.
Hakin-Smith et al. [58]
Sarcoma Southern blot Short tumor TL associated with genomic instability and a worse outcome. Avigad et al. [59]
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forme, patients with tumors displaying an ALT phenotype had a
more favorable outcome [58].
Hence, although not entirely consistent, most studies have
indicated that tumor TL alterations are associated with a worse
clinical outcome. The type of alteration linked to a poorer survival
(short vs. long TL) might depend on the tumor type. At the present
time, the underlying mechanisms remain unclear. As for short TL and
its association to a poorer outcome, it is logical to consider the relation
between short TL and genomic instability. It has previously been
reported that TL abnormalities occur early in the carcinogenic process
[13,14]. The association between long telomeres and a poorer clinical
outcome can only be speculated upon. For the tumor types concerned,
it might be that telomerase is more highly expressed in advanced
tumors. Indeed, in hepatocellular carcinoma, Oh et al. [49] reported
that tumors of advanced stages displayed high telomerase activity and
long telomeres. It is not unreasonable to think that long telomeres in
the tumor reﬂect telomere stabilization which might be of advantage
for tumor progression.
5. Blood telomere length as a potential predictor for cancer risk
and prognosis
There is a need for reliable, easilymeasurable biologicalmarkers for
risk assessment and prognostication of malignancies. In recent years, a
growing number of studies have focused on analyzing telomeres in
peripheral blood cells in relation to cancer risk. Since blood is an easily
accessible biological sample, blood TL is an interesting candidate as a
biological marker. However, previous reports from this research area
are not unequivocal. A summary of publications and their mainﬁndings are shown in Table 3 [19,55,60–67]. In renal [63,67], lung
[63,64], bladder [63,65], head and neck [63] and oesophagus [66]
carcinomas, short TL in peripheral blood have been associated with
increased cancer risk. Similar data have been reported for malignant
lymphoma [68]. Regarding breast cancer, a study in sister sets found a
non-signiﬁcant association between short TL and increased cancer risk
[60]. In contrast, in newly diagnosed womenwith spontaneous breast
tumors, cancer risk increased with increasing TL [62]. In yet another
study, no signiﬁcant differences in TL were found between breast
cancer patients and controls, or between affected women before and
after treatment [61]. In a recent study on skin cancer, long blood TLwas
associatedwith a higher risk ofmelanoma but a lower risk of basal-cell
carcinoma, whereas no obvious associationwas found between TL and
risk of squamous-cell carcinoma [19]. Hence, the majority of studies
have found blood TL alterations in cancer patients when compared to
healthy controls. It might be that the type of TL alteration differs
depending on the tumor type. Differences in the methodology of
measuring TLmight also contribute to the discrepancy. In addition, the
type of blood cells that are analyzed can vary between different studies
(i.e. buffy coats vs. lymphocytes etc.). However, in the skin cancer
study [19], different TL alterationswere found in different tumor types,
even though the method for measuring TL (real-time PCR) was the
same for all tumors.
The biological mechanism(s) behind the reported association
between blood TL alterations and increased cancer risk is not clear. For
example, it is not evident whether the TL alterations observed in
peripheral blood reﬂect a secondary phenomenon caused by the
cancer disease, or if the alterations are in fact part of the cancer
etiology; or both. Oxidative stress has been associated with tissue
aging [69] as well as telomere shortening [1], and it has been proposed
Table 3
Summary of studies investigating blood telomere length as a marker for risk and/or prognosis in solid malignancies
Tumor type Method for TL determination Main ﬁndings Reference
Breast Tel-PCR A non-signiﬁcant association found between short telomeres in leukocytes and increased
breast cancer risk.
Shen et al. [60]
Southern blot No signiﬁcant differences in TL detected between breast cancer patients and controls, or
between affected women before and after treatment.
Barwell et al. [61]
Tel-PCR Breast cancer risk increased with increasing blood TL. Long TL (Nmedian) found to be an
independent negative prognostic factor.
Svenson et al. [62]
Lung Q-FISH and Southern blot Short TL in lymphocytes associated with increased risk of lung cancer Wu et al. [63]
Tel-PCR Lung cancer risk increased with decreasing lymphocyte TL. Strongest association between
short TL and increased cancer risk found in patients with small cell carcinoma, as
compared to squamous cell carcinoma and adenocarcinoma.
Jang et al. [64]
Bladder Q-FISH and Southern blot Bladder cancer risk increased with decreasing lymphocyte TL. Wu et al. [63]
Tel-PCR Short TL associated with increased risk of bladder cancer. Differences in TL across
categories of pack-years of smoking and between genders observed.
McGrath et al. [65]
Oesophagus Tel-PCR Short leukocyte TL associated with increased risk of oesophageal adenocarcinoma in
patients with Barrett's oesophagus, most notably among NSAID nonusers, ever smokers,
and patients with low waist-to-hip ratio
Risques et al. [66]
Skin Tel-PCR Long TL associatedwith an increased risk of melanoma. In basal-cell carcinoma, cancer risk
increased with decreasing TL. No clear trend between TL and risk in squamous-cell
carcinoma.
Han et al. [19]
Head and neck Q-FISH and Southern blot Short lymphocyte TL associated with increased risk of head and neck cancer. Wu et al. [63]
Kidney Q-FISH and Southern blot Short lymphocyte TL associated with increased risk of renal cell carcinoma. Wu et al. [63]
Q-FISH Short telomeres in CD4+ T cells, as well as in CD8+ T cells and overall peripheral blood
lymphocytes, associated with increased risk of renal cell carcinoma.
Shao et al. [67]
Tel-PCR A strong association found between long blood TL (4th quartile) and a poor outcome in
non-metastatic patients. Blood TL found to be an independent prognostic indicator
Svenson et al. [55]
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registered in the telomeres of leukocytes [70]. Accordingly, it has been
speculated that blood TL may act as a surrogate marker of tissue
dysfunctions. In 2003, Wu et al. [63] measured TL in peripheral
lymphocytes and found an association between short TL and increased
risk of bladder, head and neck, lung and renal cell cancers. The authors
proposed telomere dysfunction as a potential predisposition factor for
cancer development. Indeed, as has been mentioned previously, there
is an association between telomere shortening and genetic instability,
and between genetic instability and increased risk of tumor formation
[3]. However, not only short TL but also long TL has been associated
with increased cancer risk, and in addition, there is still the cause and
effect question. It cannot be excluded that the disease itself, or
responses to the disease, causes a systemic effect which directly or
indirectly affects the telomere length of peripheral blood cells. The
immune response to the tumor might need to be considered. For
example, inﬂammatory components, such as cytokines and reactive
oxygen species, may have an impact on leukocyte TL. A number of
cytokines have shown potential to activate telomerase [71–75]
whereas oxidative stress, as mentioned above, might increase
telomere attrition [1]. The proliferation rate of immune cells, and
hence the telomere attrition rate, may also differ depending of the
state of the immune system, which in turnmight be altered due to the
presence of a tumor.
It was previously reported that the inter-individual TL variation
was reduced in the healthy oldest old (≥85 years) [76]. The authors
had hypothesized that healthy old individuals without age-related
diseases, such as cancer or cardiovascular disease, would have
unusually long telomeres. The study, however, showed that this was
not the case. The authors speculated that a telomere length in the
“normal range” may be most protective against tumor development,
since long telomeres may favor escape from senescence, whereas
short TL may cause genomic instability.
One problemwhen discussing blood TL and cancer risk is thatmost
studies have been cross-sectional. Large longitudinal studies are
needed in order to fully examine whether blood TL may act as a
predictor for tumor development.We recently conducted such a study
[77] by measuring TL in two blood samples collected at ∼10 years
interval from 959 individuals. Of these, 343 persons were diagnosedwith cancer after the second blood sample. Surprisingly, no difference
in blood TL was observed between cases and controls, and the
telomere attrition rate was similar for the two groups. These results
indicate that blood TL might not be a predictor for cancer develop-
ment per se, but since the patients suffered from a variety of tumors, it
is still possible that blood TL can act as a biomarker for speciﬁc tumor
types, as has been suggested by the previous cross-sectional studies.
An interesting ﬁnding in our longitudinal study was that the telomere
attrition rate was highly correlated to the TL at baseline, meaning that
individuals with the longest telomeres at base line showed the most
pronounced TL shortening over time and vice versa. Aviv et al. [78]
recently published similar results, showing that age-dependent TL
shortening was proportional to leukocyte TL at baseline. In both
studies, a subcohort of participants even showed increased TL over
time. These results add to the complexity of telomere dynamics
through life.
Studies investigating blood telomere length as a prognostic
indicator in malignancies are sparse [55,62]. We previously reported
that newly diagnosed women with breast cancer had longer blood
telomeres than controls [62]. Moreover, women with the longest
blood TL (Nmedian) had a signiﬁcantly worse prognosis compared to
women with shorter telomeres. Interestingly, blood TL was found to
be an independent prognostic marker. In a recent study [55], we
investigated TL in peripheral blood, kidney cortex, and tumors of
patients with clear cell renal cell carcinoma. Importantly, and similar
to our breast cancer study, patients with the longest blood TL (4th
quartile) had a signiﬁcantly worse prognosis compared to patients
with shorter blood TL. Again, blood TL turned out to be an
independent prognostic indicator. In contrast, TL in kidney cortex or
tumor tissues did not predict survival when comparing TL quartiles.
The reason to why patients with long leukocyte TL showed a poorer
outcome compared to patients with shorter TL remains unclear and
can only be speculated upon. Nevertheless, our ﬁndings indicate that
blood TL is a prognostic indicator, which could be of importance for
future treatment strategies. A question to be solved, however, is how
TL measurements could become valuable not only for large groups,
but also for single individuals. Setting a “normal range” regarding TL is
difﬁcult, due to the large inter-individual variability in TL among
individuals of the same age.
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For proper evaluation of TL as biomarker in malignancy it is
necessary to recognize the complexity of telomere maintenance and
the fact that we still lack much information on this issue. The
methodology used for TL measurements might have an impact but it
seems as if Southern blotting, ﬂow-FISH and Tel-PCR all give relevant
information provided that proper controls are used, even though it
might be difﬁcult to directly compare data between laboratories.
Regarding TL abnormalities in malignant cells and clinical outcome
the picture is multifaceted. For hematogical malignancies the
published data are in good agreement for MDS, CML and CLL, showing
that short telomeres indicate progressive disease and a poor outcome.
For solid tumors the data are more heterogeneous. A possible
prognostic impact of TL abnormalities seems to be tumor type
dependent and more data on well characterized tumor materials are
required. It is evident that the appearance of a malignancy affects the
whole body, and it is possible that the alterations in blood TL seen at
diagnosis reﬂect responses to the tumor. Similar as for solid tumors,
the reported TL alterations in blood seem to differ between tumor
types. Of most interest is perhaps the fact that blood TL appear to
constitute a signiﬁcant prognostic indicator, but additional studies on
different patient cohorts are needed in order to further substantiate
this indication. Large longitudinal studies and improved standardized
protocols are needed for the future, to fully be able to evaluate TL as a
marker in malignancies.
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